rhGM-CSF作为成人乙肝疫苗无(弱)应答者免疫佐剂初探

Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine.     

rhGM-CSF作为成人乙肝疫苗无(弱)应答者免疫佐剂初探

目的 探讨重组人粒细胞.巨噬细胞集落刺激因子(rhGM-CSF)对提高成人乙肝疫苗无(弱)应答免疫的作用.方法 将两年内完成1～2个标准乙肝疫苗接种程序、复查HBV标志物均阴性的健康人群随机分为A、B两组.A组:33人,按标准免疫程序予10μg乙肝疫苗;B组:34人,先予rhGM-CSF 300μg皮下注射,次日始按A组方案予乙肝疫苗.接种首针后第1、2、8个月(T1、T2、T8)采血检测抗-HBs.结果 A、B组T8抗-HBs阳性率分别为39.39%和64.71%(P=0.038);A组三次抗体滴度检测结果 无显著性变化;B组升高明显,分别为(113.85±198.56)mIU/ml,(312.40±349.44)mIU/ml,(427.74±411.58)mIU/ml(P=0.001).A组和B组T8抗体水平差异有统计学意义(P=0.010).结论 rhGM-CSF联合乙肝疫苗复种对无(弱)应答者免疫效果优于单纯复种,GM-CSF具有提高机体对乙肝疫苗免疫应答的能力.     

来自霍乱疫区船舶及其货物管理

本文对来自霍乱疫区船舶及其货物管理进行了初步探讨。强调对来自霍乱疫区的船舶及其货物进行管理的重要性,提示我们应进一步加强来自霍乱疫区船舶及其货物的管理,提高警惕、常备不懈,有效地防止霍乱的传入。     

rhGM-CSF作为成人乙肝疫苗无(弱)应答者免疫佐剂初探

Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine.     

番禺口岸3例HIV感染者流行病学分析

对2001年至2005年经番禺口岸出入境的港、澳、台同胞、出国人员以及交通员工进行HIV血清学检测,从上述人员中检出3例HIV感染者,均为男性患者,其中1例是台湾人、1例是广西人、1例是本地人;其职业分别是台湾商人、港澳船员,当地无业(吸毒)人员;均为HIV-1抗体阳性.经流行病学调查,3例HIV阳性者共同的感染特点是均有治游史,性伴侣多且不固定,经常不采取安全措施,对感染艾滋病的途径缺乏了解,自我防护意识极差;感染途径可能与暴露性接触和共同使用吸毒针头有关.作者提出应加强对来自艾滋病高发国家和地区的出入境人员的HIV监测,防止因高危人群的漏检而造成危险传染源的输入.利用一切可利用的途径大力宣传预防艾滋病的知识,同时做好HIV感染者的后续监测工作,保障其合法权益不受侵犯,以减少HIV进一步传播的风险.     

交通事故伤害4752宗的流行病学分析

目的　探讨交通事故意外伤害的高危人群,高危车种和高发时间,以揭示车祸发生的危险因素。方法　用流行病学原理对番禺市１９９７年发生的４ ７５２宗交通事故（车祸）伤害进行回顾分析。结果　全年共发生交通事故４ ７５２ 宗,造成２６８ 人死亡,３ ２０２ 人受伤,死亡率为２０．９４／１０ 万。高发年龄是２０～４９ 岁的青壮年,男性车祸死亡率（２９．４５／１０ 万）是女性死亡率（１２．４６／１０ 万）的２．３６ 倍;骑自行车者和行人特别是老年人是车祸的高危人群,共死亡１２４ 人,占总死亡人数的４７．４６％ ;摩托车是造成交通事故的高危车种,全年摩托车发生车祸１０１ 宗,死亡１０５ 人,占总死亡宗数的４０．４０％ ,车辆死亡率为５．８４／万辆。而交通事故的高发时间是夜间（１７：００～２４：００）,共发生车祸１ ７０９宗,死亡１１６ 人,占总死亡人数４３．２８％ 。结论　预防和控制车祸的对策是加强群众性的交通安全教育,改善道路安全设施和限制摩托车上牌     

出境留学生入学相关医学健康咨询问题的探讨

通过总结多个国家和地区对出境留学生入学前健康状况评估和/或预防接种的不同要求,对出境留学生健康评估和/或预防接种过程中的评估内容、评估重点、注意事项等进行探讨,为如何做好出境留学生医学健康咨询工作提供参考。     

登革出血热的常识问答

登革出血热的定义是什么? 人感染登革病毒后可引起一系列的疾病,从轻微的非典型病毒症候群到严重的出血性疾病和死亡,疾病的严重出血形式就称为登革出血热(DHF)和登革休克综合征(DSS)。 目前已知的病毒种类有哪些? 病毒有4种血清型,分别称为DEN-1、DEN—2、DEN—3、DEN—4。     

rhGM-CSF作为成人乙肝疫苗无(弱)应答者免疫佐剂初探

Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine.     

rhGM-CSF作为成人乙肝疫苗无(弱)应答者免疫佐剂初探

Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine.